(UTHR) United Therapeutics - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 23.937m USD | Total Return: 84.1% in 12m

Vasodilators, Monoclonal Antibodies, Infusion Pumps, Xenotransplantation
Total Rating 70
Safety 95
Buy Signal -0.04
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.5
Market Cap: 23.9B
Avg Turnover: 217M
Risk 3d forecast
Volatility32.1%
VaR 5th Pctl4.62%
VaR vs Median-16.8%
Reward TTM
Sharpe Ratio1.36
Rel. Str. IBD85.6
Rel. Str. Peer Group65.3
Character TTM
Beta0.585
Beta Downside0.390
Hurst Exponent0.372
Drawdowns 3y
Max DD33.00%
CAGR/Max DD1.19
CAGR/Mean DD4.25
EPS (Earnings per Share) EPS (Earnings per Share) of UTHR over the last years for every Quarter: "2021-03": 0.61, "2021-06": 3.65, "2021-09": 3.42, "2021-12": 2.35, "2022-03": 5.03, "2022-06": 2.41, "2022-09": 4.91, "2022-12": 2.67, "2023-03": 4.86, "2023-06": 5.24, "2023-09": 5.38, "2023-12": 4.36, "2024-03": 6.17, "2024-06": 5.85, "2024-09": 6.39, "2024-12": 6.19, "2025-03": 6.6296, "2025-06": 6.41, "2025-09": 7.16, "2025-12": 7.7, "2026-03": 5.82,
EPS CAGR: 18.31%
EPS Trend: 97.9%
Last SUE: -3.20
Qual. Beats: -1
Revenue Revenue of UTHR over the last years for every Quarter: 2021-03: 379.1, 2021-06: 446.5, 2021-09: 444.7, 2021-12: 415.2, 2022-03: 461.9, 2022-06: 466.9, 2022-09: 516, 2022-12: 491.5, 2023-03: 506.9, 2023-06: 596.5, 2023-09: 609.4, 2023-12: 614.7, 2024-03: 677.7, 2024-06: 714.9, 2024-09: 748.9, 2024-12: 735.9, 2025-03: 794.4, 2025-06: 798.6, 2025-09: 799.5, 2025-12: 790.2, 2026-03: 781.5,
Rev. CAGR: 17.18%
Rev. Trend: 97.4%
Last SUE: -0.51
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: UTHR United Therapeutics

United Therapeutics Corporation is a biotechnology firm focused on chronic and life-threatening conditions, primarily pulmonary arterial hypertension (PAH) and pediatric oncology. The company’s portfolio centers on treprostinil-based therapies delivered through various modalities, including dry powder inhalers, nebulizers, and subcutaneous pumps. Beyond its core PAH franchise, the firm is advancing a pipeline of monoclonal antibodies and regenerative medicine projects, including xenotransplantation and organ bioengineering.

The biotechnology sector is characterized by high research and development intensity, where companies often rely on patent protection and proprietary delivery systems to maintain market share against generic competition. United Therapeutics utilizes a vertically integrated business model that combines drug formulation with medical device engineering to improve patient compliance and therapeutic outcomes. For a deeper look into these fundamentals, you may find further insights on ValueRay.

Recent strategic initiatives include collaborations with DEKA and MannKind to refine drug-delivery technologies and the development of gene-edited porcine organs for human transplantation. These long-term projects aim to address the global shortage of donor organs, representing a shift from traditional pharmacology toward complex bioengineering solutions.

Headlines to Watch Out For
  • Tyvaso DPI adoption and market expansion drive significant revenue growth
  • Clinical trial results for idiopathic pulmonary fibrosis treatment impact long-term valuation
  • Treprostinil franchise faces potential erosion from generic competition and new entrants
  • Xenotransplantation pipeline progress dictates future diversification and speculative stock premium
  • Medicare reimbursement policy changes influence pricing power and net profit margins
Piotroski VR-10 (Strict) 6.5
Net Income: 1.29b TTM > 0 and > 6% of Revenue
FCF/TA: 0.15 > 0.02 and ΔFCF/TA 0.57 > 1.0
NWC/Revenue: 71.70% < 20% (prev 107.5%; Δ -35.78% < -1%)
CFO/TA 0.23 > 3% & CFO 1.56b > Net Income 1.29b
Net Debt/EBITDA: error (cannot be calculated)
Current Ratio: 4.79 > 1.5 & < 3
Outstanding Shares: last quarter (47.2m) vs 12m ago -2.88% < -2%
Gross Margin: 86.58% > 18% (prev 0.89%; Δ 8.57k% > 0.5%)
Asset Turnover: 43.85% > 50% (prev 38.66%; Δ 5.18% > 0%)
Interest Coverage Ratio: 99.37 > 6 (EBITDA TTM 1.72b / Interest Expense TTM 16.4m)
Altman Z'' 10.00
A: 0.34 (Total Current Assets 2.87b - Total Current Liabilities 599.1m) / Total Assets 6.71b
B: 1.32 (Retained Earnings 8.83b / Total Assets 6.71b)
C: 0.23 (EBIT TTM 1.63b / Avg Total Assets 7.23b)
D: 10.85 (Book Value of Equity 8.82b / Total Liabilities 813.1m)
Altman-Z'' = 19.42 = AAA
Beneish M -3.12
DSRI: 0.92 (Receivables 312.0m/322.0m, Revenue 3.17b/2.99b)
GMI: 1.03 (GM 86.58% / 89.00%)
AQI: 0.92 (AQ_t 0.30 / AQ_t-1 0.32)
SGI: 1.06 (Revenue 3.17b / 2.99b)
TATA: -0.04 (NI 1.29b - CFO 1.56b) / TA 6.71b)
Beneish M = -3.12 (Cap -4..+1) = AA
What is the price of UTHR shares?

As of May 23, 2026, the stock is trading at USD 565.87 with a total of 380,280 shares traded.
Over the past week, the price has changed by -0.03%, over one month by -1.02%, over three months by +19.79% and over the past year by +84.12%.

Is UTHR a buy, sell or hold?

United Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy UTHR.

  • StrongBuy: 6
  • Buy: 2
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the UTHR price?
Analysts Target Price 663.6 17.3%
United Therapeutics (UTHR) - Fundamental Data Overview as of 22 May 2026
P/E Trailing = 20.8554
P/E Forward = 20.6612
P/S = 7.5516
P/B = 4.0773
P/EG = 2.3219
Revenue TTM = 3.17b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.72b USD
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = unknown
 Net Debt = unknown
 Enterprise Value = 21.78b USD (23.94b + (null Debt) - CCE 2.15b)
Interest Coverage Ratio = 99.37 (Ebit TTM 1.63b / Interest Expense TTM 16.4m)
EV/FCF = 21.42x (Enterprise Value 21.78b / FCF TTM 1.02b)
FCF Yield = 4.67% (FCF TTM 1.02b / Enterprise Value 21.78b)
FCF Margin = 32.08% (FCF TTM 1.02b / Revenue TTM 3.17b)
Net Margin = 40.61% (Net Income TTM 1.29b / Revenue TTM 3.17b)
Gross Margin = 86.58% ((Revenue TTM 3.17b - Cost of Revenue TTM 425.3m) / Revenue TTM)
Gross Margin QoQ = 82.93% (prev 86.91%)
Tobins Q-Ratio = 3.24 (Enterprise Value 21.78b / Total Assets 6.71b)
 Interest Expense / Debt = unknown (Interest Expense 3.00m / Debt none)
 Taxrate = 13.63% (43.4m / 318.3m)
NOPAT = 1.41b (EBIT 1.63b * (1 - 13.63%))
Current Ratio = 4.79 (Total Current Assets 2.87b / Total Current Liabilities 599.1m)
 Debt / Equity = unknown (Debt none)
 Debt / EBITDA = unknown (Net Debt none / EBITDA 1.72b)
 Debt / FCF = unknown (Net Debt none / FCF TTM 1.02b)
 Total Stockholder Equity = 6.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.81% (Net Income 1.29b / Total Assets 6.71b)
RoE = 19.24% (Net Income TTM 1.29b / Total Stockholder Equity 6.69b)
RoCE = 26.65% (EBIT 1.63b / Capital Employed (Total Assets 6.71b - Current Liab 599.1m))
RoIC = 35.53% (NOPAT 1.41b / Invested Capital 3.96b)
WACC = 8.04% (E(23.94b)/V(23.94b) * Re(8.04%) + (debt-free company))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -2.35%
[DCF] Terminal Value 79.62% ; FCFF base≈1.06b ; Y1≈1.22b ; Y5≈1.80b
[DCF] Fair Price = 688.3 (EV 29.22b - Net Debt 0.0 = Equity 29.22b / Shares 42.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 3.0% )
EPS Correlation: 97.87 | EPS CAGR: 18.31% | SUE: -3.20 | # QB: -1
Revenue Correlation: 97.39 | Revenue CAGR: 17.18% | SUE: -0.51 | # QB: 0
EPS current Quarter (2026-06-30): EPS=6.99 | Chg30d=+0.07% | Revisions=+8% | Analysts=11
EPS next Quarter (2026-09-30): EPS=7.13 | Chg30d=+1.01% | Revisions=-8% | Analysts=11
EPS current Year (2026-12-31): EPS=27.42 | Chg30d=-3.43% | Revisions=-29% | GrowthEPS=-1.6% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=32.10 | Chg30d=-1.76% | Revisions=+0% | GrowthEPS=+17.1% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: -29%